In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 55% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED WITHIN 6 MONTHS OF DIAGNOSIS VS PLACEBO1*
Time to first disease progression event in patients treated within 6 months of PAH diagnosis
![Percent of patients treated within 6 months of PAH diagnosis without an event desktop curve](/assets/images/3.3_53-percent-km_chart.png)
![Percent of patients treated within 6 months of PAH diagnosis without an event mobile curve](/assets/images/3.3_53-percent-km_chart--mobile.png)
![55% risk reduction HR 0.45 (95% CI: 0.33, 0.63)](/assets/images/3.3_risk-reduction_square.png)
Baseline patient characteristics
- GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
- 35% (n=404) of all patients in GRIPHON were treated ≤6 months from diagnosis (52% FC II and 46% FC III)†
- 41% were receiving PDE-5i monotherapy, 39% were receiving no background PAH therapy, 10% were receiving ERA monotherapy, and 10% were receiving an ERA + PDE-5i at baseline
- Mean age: UPTRAVI® (44 years), placebo (44 years)
- FC II: UPTRAVI® (55%), placebo (49%)
Summary of primary endpoint events in patients treated within 6 months of PAH diagnosis
![Events in patients treated within 6 months of PAH diagnosis desktop table](/assets/images/3.3_primary-endpoint_table.png)
![Events in patients treated within 6 months of PAH diagnosis mobile table](/assets/images/3.3_primary-endpoint_table1--mobile.png)
Adverse reactions in ≤6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%
![Adverse reactions in ≤6 months from diagnosis subgroup notably different from overall population mobile table](/assets/images/3.3_adverse-reactions_table-1--mobile.png)
The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.
In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 26% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED AFTER 6 MONTHS OF DIAGNOSIS VS PLACEBO1*
Time to first disease progression event in patients treated after 6 months of PAH diagnosis
![Percent of patients treated after 6 months of PAH diagnosis without an event desktop curve](/assets/images/3.3_26-percent-km_chart.png)
![Percent of patients treated after 6 months of PAH diagnosis without an event mobile curve](/assets/images/3.3_26-percent-km_chart--mobile.png)
![26% risk reduction HR 0.74 (95% CI: 0.57, 0.96)](/assets/images/3.3_risk-reduction_square-2.png)
Baseline patient characteristics
- GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
- 65% (n=752) of all patients in GRIPHON were treated >6 months from diagnosis (56% FC III, 42% FC II)†
- 28% were receiving PDE-5i monotherapy, 11% were not receiving PAH background therapy, 17% were receiving ERA monotherapy, and 45% were receiving an ERA + PDE-5i at baseline
- Mean age: UPTRAVI® (50 years), placebo (50 years)
- FC II: UPTRAVI® (44%), placebo (41%)
Summary of primary endpoint events in patients treated after 6 months of PAH diagnosis
![Events in patients treated within and after 6 months of PAH diagnosis desktop table](/assets/images/3.3_primary-endpoint_table-after-6-mo.png)
![Events in patients treated within and after 6 months of PAH diagnosis mobile table](/assets/images/3.3_primary-endpoint_table1-after-6-mo--mobile.png)
Adverse reactions in >6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%
![Adverse reactions in >6 months from diagnosis subgroup notably different from overall population mobile table](/assets/images/3.3_adverse-reactions_table-2--mobile.png)
The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.